Thermo Fisher bags single-use bioreactor tech partner Finesse

By Dan Stanton contact

- Last updated on GMT

Image: iStock/designer491
Image: iStock/designer491

Related tags: Thermo fisher, Life, Technology, Biology

Thermo Fisher Scientific says it is buying Finesse Solutions, its long-term supplier of measurement and control solutions for bioprocessing applications.

The deal announced yesterday, adds bioprocess management technology Finesse Solutions to Thermo Fisher’s life sciences business.

CEO Marc Casper said the Santa Clara, California-based firm has been a technology partner since 2013, and its universal control system which combines with Thermo Fisher’s own single-use technologies will “strengthen our position in the high-growth bioproduction market.”

Finesse’s Smart technology suite offers a range of data management software, and bioreactor controllers and sensors which allow bioprocessing firms and drugmakers to configurate biomanufacturing processes from labscale to cGMP-compliant production.

Finesse generated around $50m in revenue last year. Financial details of the deal were not divulged, but Thermo Fisher expects the deal to close in the next few days, having received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

M&A

The deal is the latest in a string of acquisitions made in the life science space by Thermo Fisher.

Last year the firm bought biological analysis firm Affymetrix​ for $1.3bn, analytical instrument firm FEI Company​ for $4.2bn, and stem cell tech and reagent business MTI-GlobalStem​. 2015 saw the company add disposable technology firm ASI to its bioprocessing arsenal for $300m, and a year earlier Life Technologies​ was acquired for $13bn.

Thermo Fisher was also rumoured to be interested in buying downstream disposable tech firm Pall Corporation – since acquired by Danaher for $13bn​ – and last summer was allegedly eyeing up Illumina for $30bn​.

During a call to discuss its Q4 results late last month, Casper told investors his firm continued to look at a number of M&A opportunities.

“The industry is incredibly fragmented,”​ he said. “So we follow our strategy of looking at things that will strengthen the company strategically, clearly be understood and valued by our customers and create shareholder value, with the primary metric being return on invested capital.”

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers